Published: 14 June 2026 | 6.00 AM
Last Updated: 14 June 2026 | 6.00 AM
IPO Overview / Intro
Avience Biomedicals IPO is an SME book building issue. The IPO consists entirely of a fresh issue of 14,53,800 equity shares. The issue size in Rupee terms will be updated after the company announces the final price band.
The IPO opens for subscription on 18 June 2026 and closes on 22 June 2026. The shares are proposed to be listed on NSE SME with a tentative listing date of 25 June 2026.
Avience Biomedicals Ltd is an ISO-certified diagnostics and medical technology company engaged in manufacturing, supplying and exporting molecular diagnostic solutions, rapid test kits, medical devices, analyzers and biotechnology products catering to pathology laboratories, hospitals, research centres and healthcare institutions.
Key Highlights
| Particulars |
Details |
| IPO Type |
SME Book Building IPO |
| Issue Size |
To Be Declared |
| Fresh Issue |
14,53,800 Equity Shares |
| Offer For Sale |
Nil |
| Price Band |
To Be Declared |
| Face Value |
Rs. 10 Per Share |
| Listing Exchange |
NSE SME |
| Lot Size |
To Be Declared |
| Retail Application |
To Be Declared |
| Market Cap |
To Be Declared |
| Listing Date |
25 June 2026 (Tentative) |
👉 | IPO GMP | IPO Reviews | IPO Subscription | IPO Allotment
Avience Biomedicals IPO GMP – Latest Update
| GMP Details |
Value |
| Avience Biomedicals IPO GMP Today |
Updating Soon |
| Kostak Rate |
Updating Soon |
| Allotted Applications |
Updating Soon |
Avience Biomedicals IPO Subscription Status – Live Update
| Category |
Subscription |
| QIB Category |
Updating Soon |
| NII Category |
Updating Soon |
| Retail Category |
Updating Soon |
| Total Subscription |
Updating Soon |
IPO Details at a Glance
| Particulars |
Details |
| IPO Date |
18 June 2026 to 22 June 2026 |
| Listing Date |
25 June 2026 |
| Face Value |
Rs. 10 Per Share |
| Price Band |
To Be Declared |
| Lot Size |
To Be Declared |
| Issue Type |
Book Building IPO |
| Listing At |
NSE SME |
| Total Issue Size |
14,53,800 Shares |
| Reserved for Market Maker |
82,200 Shares |
| Fresh Issue |
14,53,800 Shares |
| Offer For Sale |
Nil |
| Net Offered to Public |
13,71,600 Shares |
| Issue Size |
To Be Declared |
| Shareholding Pre Issue |
40,31,256 Shares |
| Shareholding Post Issue |
54,85,056 Shares |
| Market Cap |
To Be Declared |
IPO Timetable
| Event |
Date |
| IPO Open Date |
18 June 2026 |
| IPO Close Date |
22 June 2026 |
| Basis of Allotment |
23 June 2026 |
| Refund Initiation |
24 June 2026 |
| Credit of Shares |
24 June 2026 |
| Listing Date |
25 June 2026 |
Reservation
| Investor Category |
Reservation |
| QIB Shares Offered |
6,83,400 Shares (49.83%) |
| Anchor Investor Shares Offered |
4,09,800 Shares (28.19%) |
| QIB Ex-Anchor Shares Offered |
2,73,600 Shares (18.82%) |
| NII Shares Offered |
2,07,000 Shares (15.09%) |
| bNII Shares Offered |
1,38,000 Shares (9.49%) |
| sNII Shares Offered |
69,000 Shares (4.75%) |
| Retail Shares Offered |
4,81,200 Shares (35.08%) |
| Market Maker Reservation |
82,200 Shares (5.65%) |
| Total Shares Offered |
14,53,800 Shares (100.00%) |
Lot Size
| Application Type |
Lots |
Shares |
Amount |
| Retail Minimum |
To Be Declared |
To Be Declared |
To Be Declared |
| Retail Maximum |
To Be Declared |
To Be Declared |
To Be Declared |
| S-HNI Minimum |
To Be Declared |
To Be Declared |
To Be Declared |
| S-HNI Maximum |
To Be Declared |
To Be Declared |
To Be Declared |
| B-HNI Minimum |
To Be Declared |
To Be Declared |
To Be Declared |
Company Details
Avience Biomedicals Ltd was incorporated in June 2024 and is an ISO-certified company specialising in manufacturing, supplying and exporting molecular diagnostic solutions with a focus on biotechnology, genomics and the in-vitro diagnostics industry.
The company has expanded its product portfolio from rapid diagnostic kits to a broad range of medical devices, molecular diagnostic products, serology products, biochemistry analyzers and healthcare equipment. It serves pathology laboratories, microbiology laboratories, hospitals, research centres and healthcare institutions across India and overseas markets.
Apart from manufacturing activities, the company also operates as a distributor and trader of medical equipment. Its manufacturing facility is located in Noida, Uttar Pradesh.
The product portfolio includes rapid test kits, molecular diagnostic kits, biochemistry analyzers and reagents, hematology analyzers, oxygen concentrators, viral transport media and other medical devices. As of 31 January 2026, the company had 75 permanent employees and 33 contractual employees.
Competitive Strengths
| Key Strengths |
| Strong Industry Experience and Expertise |
| Diversified Diagnostic and Medical Device Portfolio |
| Growing Distribution Network Across India and Overseas Markets |
| Cost-Effective and Affordable Healthcare Solutions |
| Stringent Quality Control and Regulatory Compliance |
IPO Objects
| Sr. No. |
Objects of the Issue |
Amount |
| 1 |
Capital Expenditure Towards New Manufacturing Unit at Medical Device Park, YEIDA, Uttar Pradesh |
Rs. 15.96 Crore |
| 2 |
Funding Working Capital Requirements |
Rs. 8.25 Crore |
| 3 |
General Corporate Purposes |
Balance Amount |
| Total |
Total Objects |
Rs. 24.21 Crore |
Company Address
| Particulars |
Details |
| Registered Office |
C-11, Block-C, Community Centre, Janakpuri A-3, New Delhi – 110058 |
| Phone |
1800-12-04-636 |
| Email |
info@avienbio.com |
Lead Manager & Registrar
| Particulars |
Details |
| Lead Manager |
Fintellectual Corporate Advisors Pvt. Ltd. |
| Registrar |
Skyline Financial Services Pvt. Ltd. |
| Registrar Contact |
02228511022 |
| Registrar Email |
ipo@skylinerta.com |
| Market Maker |
Asnani Stock Broker Pvt. Ltd. |
Financials
| Particulars (Rs. Crore) |
FY2025 |
FY2024 |
FY2023 |
| Total Assets |
43.60 |
25.63 |
10.02 |
| Total Income |
29.54 |
16.64 |
10.93 |
| Profit After Tax |
5.19 |
1.99 |
0.78 |
| EBITDA |
7.65 |
3.15 |
1.43 |
| Net Worth |
20.60 |
6.07 |
4.08 |
| Reserves & Surplus |
16.57 |
2.79 |
0.79 |
| Total Borrowings |
13.75 |
7.73 |
2.66 |
Valuation
Key Performance Indicators (KPI)
| KPI |
FY2025 |
| ROE |
38.64% |
| ROCE |
21.68% |
| Debt / Equity |
0.67 |
| RoNW |
38.64% |
| EBITDA Margin |
26.49% |
| Price to Book Value |
To Be Declared |
EPS & Valuation
| Particulars |
Pre IPO |
Post IPO |
| EPS (Rs.) |
To Be Declared |
To Be Declared |
| P/E (x) |
To Be Declared |
To Be Declared |
Shareholding Pattern
| Particulars |
Pre Issue |
Post Issue |
| Promoter Holding |
87.89% |
64.59% |
Chanakya View
Investment Summary
| Parameter |
Observation |
| Business Segment |
Molecular Diagnostics & Medical Devices |
| Industry Outlook |
Positive |
| Product Portfolio |
Diversified |
| Profitability |
Strong |
| Return Ratios |
Strong |
| Growth Profile |
Healthy |
| Valuation |
Awaited |
| SME Liquidity |
Moderate |
Positives
| Strengths |
| Fast Growing Diagnostics and Medical Devices Segment |
| Diversified Product Portfolio |
| Strong Profit Growth Track Record |
| Healthy Return Ratios |
| Manufacturing Expansion Planned |
| Presence Across B2B and B2G Markets |
Concerns
| Risks |
| SME Liquidity Risk |
| Regulatory Compliance Risk |
| Dependence on Healthcare Procurement Cycles |
| Competitive Diagnostics Industry |
| Working Capital Intensive Operations |
| Valuation Yet To Be Announced |
Avience Biomedicals Ltd operates in the molecular diagnostics, biotechnology and medical devices segment, which continues to benefit from increasing healthcare spending, rising diagnostic awareness and expanding healthcare infrastructure across India.
The company has demonstrated strong financial growth over the reported period. Total income increased from Rs. 16.64 crore in FY2024 to Rs. 29.54 crore in FY2025, while profit after tax improved from Rs. 1.99 crore to Rs. 5.19 crore. Return ratios remain healthy, reflecting improving operational efficiency.
The proposed IPO proceeds are expected to support manufacturing expansion through a new facility at the Medical Device Park under YEIDA and strengthen working capital requirements. This may enhance future production capacity and business scalability.
Considering the growing diagnostics market, diversified product portfolio, healthy profitability and planned capacity expansion, the IPO appears interesting from a business perspective. However, investors should evaluate the final valuation and pricing details before taking an investment decision.
FAQs
What is Avience Biomedicals IPO GMP today?
Avience Biomedicals IPO GMP today is currently unavailable as the price band has not yet been announced. Live GMP updates will be provided once grey market activity begins.
What is the Avience Biomedicals IPO price band?
Avience Biomedicals IPO price band is yet to be announced by the company.
What is the Avience Biomedicals IPO lot size?
Avience Biomedicals IPO lot size and minimum investment amount are yet to be announced.
When will Avience Biomedicals IPO list?
Avience Biomedicals IPO is expected to list on NSE SME on 25 June 2026.
Donot miss IPO GMP Live —Which IPO commands fancy?
Also Read
